KalVista presents data on HAE attacks potentially addressed by Sebetralstat

KalVista announced the presentation of a novel analysis characterizing hereditary angioedema – HAE – attacks occurring in patients receiving long-term prophylaxis treatments, or LTP, at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference in Singapore. Although LTP yields significant reductions in HAE attack frequency, many patients continue to experience attacks in all anatomic locations, including potentially life-threatening laryngeal attacks. CEO Andrew Crockett said, “Access to safe and effective on-demand therapy is essential for all people living with HAE, including those receiving LTP. Sebetralstat, an oral plasma kallikrein inhibitor in late-stage development for on-demand treatment of HAE attacks, has the potential to address this persisting unmet need.”